• • CAR (NR1I3) is upregulated in 85% of HCC tumors, and its knockout reduces cell proliferation by 45% and migration by 60% (p < 0.001), indicating a direct oncogenic role.
• • CAR directly binds to the ABCB1 promoter, increasing expression by 3.5-fold, which correlates with multidrug resistance and poor overall survival (hazard ratio = 2.3, p = 0.003).
• • A 5-NR prognostic signature stratifies HCC patients into high- and low-risk groups with 5-year survival rates of 32% vs. 78% (p < 0.0001), outperforming traditional staging.
• • Multi-omics analysis identified 12 NRs with >2-fold dysregulation (p < 0.01), providing a comprehensive landscape of NR alterations in HCC.